Muscarinic cholinergic mediation of opiate and non-opiate environmentally induced analgesias.
Previous studies have demonstrated that brief front paw shock and brief hind paw shock produce prolonged opiate and non-opiate analgesia, respectively. Additionally, opiate analgesia can be classically conditioned by using either front paw shock or hind paw shock as the unconditioned stimulus. However, beyond this point little is known regarding the neurochemistry of these phenomena. The present series of studies examined the potential involvement of nicotinic and muscarinic cholinergic systems in these 3 forms of environmentally induced analgesia. These experiments demonstrate that muscarinic cholinergic sites within the central nervous system are critically involved in the mediation of both hind paw (non-opiate) foot shock-induced analgesia ( FSIA ) and classically conditioned (opiate) analgesia since scopolamine, but not equimolar methylscopolamine, significantly attenuated analgesia. Furthermore, the primary muscarinic site(s) appears to exist at a supraspinal, rather than spinal, level since delivery of scopolamine directly to the lumbosacral cord produced, at most, only a slight decrease in analgesia. Nicotinic systems do not appear to be importantly involved in any of these forms of environmentally induced analgesias since mecamylamine had no effect on either front paw FSIA or hind paw FSIA and, at most, produced only a slight reduction in classically conditioned analgesia. These data and a review of the literature suggest that the critical cholinergic sites involved in hind paw FSIA exist within the caudal brainstem whereas cholinergic sites within more rostral brain levels probably mediate classically conditioned analgesia.
D000698:Analgesia; D000818:Animals; D002490:Central Nervous System / Q000503:physiopathology*; D002799:Cholinergic Fibers / Q000502:physiology; D003214:Conditioning, Classical / Q000502:physiology; D004597:Electroshock; D008297:Male; D008464:Mecamylamine / Q000494:pharmacology; D019832:N-Methylscopolamine; D010146:Pain / Q000503:physiopathology*; D051381:Rats; D011976:Receptors, Muscarinic / Q000502:physiology*; D012601:Scopolamine / Q000494:pharmacology; D012602:Scopolamine Derivatives / Q000494:pharmacology
D011976:Receptors, Muscarinic; D012602:Scopolamine Derivatives; D008464:Mecamylamine; D012601:Scopolamine; D019832:N-Methylscopolamine